The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

Episodic respiratory symptoms are especially common in children between ages 0 and 2 years and are not necessarily an indicator of childhood asthma. The greatest risk factor for progression from ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

As the prevalence of asthma continues to increase, the financial impact on the healthcare costs of the United States does as well. Managed care pharmacists are ideally situated to unite the shared ...

This year’s theme for World Asthma Awareness Month, “Asthma Education Empowers”, holds significant relevance given India’s current respiratory health challenges. With an escalating burden of diseases ...

Nearly 20 years after losing their son Christopher to an exercise-induced asthma attack while he was on a jog, Helen and Mike Redding’s vision to bring free, high-quality asthma treatment to children ...

The parents of a 13-year-old girl who died after an asthma attack led to a cardiac arrest have said they fear "other families will lose children because asthma is too easily dismissed".Emily Albino, ...

EDITOR’S NOTE: This story was produced with support from Broke in Philly, a collaborative reporting project on solutions to poverty and the city’s push toward economic justice. Next City is one of ...